CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,334 enrolled
Drug / intervention
brentuximab vedotin +4 moredrug
Likely dose
brentuximab vedotin 1.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01712490
NCT01712490Phase 3Completed
CompareCT.gov

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Takeda·interventional·Posted Oct 23, 2012·Updated Feb 27, 2026

In Brief

A Phase 3 clinical trial evaluating brentuximab vedotin, doxorubicin, and 3 other interventions for Hodgkin Lymphoma. Completed, enrolled 1,334 participants across 215 sites in 21 countries.

Detailed Summary

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesAustralia, Belgium, Brazil, Canada, Czechia, Denmark, France, Hong Kong, Hungary, Italy, Japan, Norway, Poland, Russia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
CollaboratorsSeagen Inc.

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2012
Enrollment StartNov 9, 2012
Primary CompletionApr 20, 2017
Study CompletionFeb 2, 2026
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.7 years ago

Interventions

brentuximab vedotindrug

Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

doxorubicindrug

Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

bleomycindrug

Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

vinblastinedrug

Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

dacarbazinedrug

Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.